We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold IART Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Integra's Specialty Surgery revenues rose 1.6% organically, led by neurosurgery and better supply reliability.
IART's adjusted EPS rose 24.4%, while Braintree production ramps up ahead of a phased SurgiMend relaunch.
High leverage and a stronger U.S. dollar pressure Integra's flexibility and reported revenue outlook.
Integra LifeSciences Holdings Corporation (IART - Free Report) sees steady demand across Specialty Surgery, supported by neurosurgery strength, better supply reliability and emerging ear, nose and throat (ENT) opportunities. The company is improving operational efficiency while ramping up Braintree production ahead of the SurgiMend relaunch. The Tissue Reconstruction portfolio is also showing gradual recovery, led by PriMatrix gains and improving Integra Skin sales. Meanwhile, high leverage and currency fluctuations remain key challenges for Integra, potentially affecting financial flexibility and reported sales.
Over the past year, this Zacks Rank #2 (Buy) stock has risen 16.1% compared with the industry’s 11.1% growth and the 16% rise of the S&P 500 composite.
The renowned medical device company has a market capitalization of $823.8 million. Integra’s earnings yield of 22.1% favorably compares to the industry’s negative 0.9% yield. In the trailing four quarters, the company delivered an average earnings surprise of 7.7%.
Let’s delve deeper.
Tailwinds for IART Stock
Specialty Surgery Demand and Portfolio Breadth: Specialty Surgery remains anchored by neurosurgery, where Integra’s products span pre-operative care, the operating room, neuro-critical care and post-care. In the second quarter of 2026, the segment’s revenues increased 1.6% organically to $309.3 million. Global Neurosurgery sales rose 1.9%, led by Certas Plus, CUSA and Bactiseal, as better supply reliability helped Integra meet customer demand more consistently.
Instruments grew 3.2% organically, and management continues to expect full-year growth. Capital equipment declined about 1% as double-digit CUSA growth was offset by smaller-ticket systems, but management maintained a positive full-year capital outlook and described the hospital capital environment as healthy. Management continues to view ENT as an emerging opportunity, with innovation focused on navigation and eustachian tube technologies.
Image Source: Zacks Investment Research
Operational Execution and Braintree Capacity Ramp-Up: Integra’s transformation program is beginning to reduce operating friction, while Braintree adds a path to restore key products. In the second quarter of 2026, adjusted EPS increased 24.4% year over year and exceeded management’s guidance range. Adjusted gross margin improved 60 basis points (bps) to 61.3%, while adjusted EBITDA margin expanded 160 bps to 18.7%. Management kept its full-year 2026 adjusted EPS guidance unchanged at $2.40-$2.50.
The company still expects $25-$30 million of savings in 2026, with another $10-$15 million of annualized savings in 2027 as remediation and transformation costs decline. Braintree began production in June 2026 and is building inventory for a phased SurgiMend relaunch later in the year. Management does not expect SurgiMend to contribute meaningfully to 2026 revenues but expects sales to recover gradually over several quarters following the relaunch. SurgiMend premarket approval (PMA) is expected earlier in 2027, with DuraSorb later that year, subject to FDA inspection and approval.
Tissue Reconstruction Recovery and Portfolio Returns: Tissue Reconstruction is supported by product breadth across biologic and synthetic wound solutions, although performance across the business remains mixed. In the second quarter of 2026, revenues were $109.5 million, down 2% organically, as DuraSorb growth and PriMatrix gains were offset by lower Integra Skin and MicroMatrix sales. Integra Skin increased sequentially from the first quarter, with management expecting that progression to continue through 2026.
Roughly nine months after its relaunch, PriMatrix had recovered slightly more than half of pre-recall revenues and continued to rise sequentially. Wound reconstruction was about flat for the first half of 2026, consistent with full-year expectations. The hospital-heavy mix also limits exposure to outpatient skin-substitute reimbursement changes. MediHoney is expected to return to the market in 2027. Continued customer interest in the product could support further recovery in the Tissue Reconstruction portfolio.
What Concerns Integra?
Elevated Leverage: Integra ended the second quarter of 2026 with total liquidity of about $496 million, including $274 million of cash and short-term investments. Net debt remained high at $1.60 billion. Total leverage improved to 4.1X from 4.5X at year-end 2025 but remained above management’s 2.5X-3.5X target range. Interest expense increased to $23.0 million from $21.0 million a year earlier. Management also expects higher interest expense in the second half of 2026 as it evaluates refinancing options, which could constrain financial flexibility.
Foreign Exchange Volatility Persists: Integra’s international exposure leaves reported revenues sensitive to currency movements. In the second quarter of 2026, management lowered full-year reported revenue guidance to $1.654-$1.695 billion from $1.662-$1.702 billion solely because of a stronger U.S. dollar.
IART Stock Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has remained constant at $2.46 in the past 60 days.
The consensus estimate for the 2026 revenues is pegged at $1.68 billion. This suggests a 2.5% rise from the year-ago reported number.
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 34.3% compared with the industry’s 11.1% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 12.2% against the industry’s 27.3% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.2% compared with the industry’s 11.1% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Should You Continue to Hold IART Stock in Your Portfolio?
Key Takeaways
Integra LifeSciences Holdings Corporation (IART - Free Report) sees steady demand across Specialty Surgery, supported by neurosurgery strength, better supply reliability and emerging ear, nose and throat (ENT) opportunities. The company is improving operational efficiency while ramping up Braintree production ahead of the SurgiMend relaunch. The Tissue Reconstruction portfolio is also showing gradual recovery, led by PriMatrix gains and improving Integra Skin sales. Meanwhile, high leverage and currency fluctuations remain key challenges for Integra, potentially affecting financial flexibility and reported sales.
Over the past year, this Zacks Rank #2 (Buy) stock has risen 16.1% compared with the industry’s 11.1% growth and the 16% rise of the S&P 500 composite.
The renowned medical device company has a market capitalization of $823.8 million. Integra’s earnings yield of 22.1% favorably compares to the industry’s negative 0.9% yield. In the trailing four quarters, the company delivered an average earnings surprise of 7.7%.
Let’s delve deeper.
Tailwinds for IART Stock
Specialty Surgery Demand and Portfolio Breadth: Specialty Surgery remains anchored by neurosurgery, where Integra’s products span pre-operative care, the operating room, neuro-critical care and post-care. In the second quarter of 2026, the segment’s revenues increased 1.6% organically to $309.3 million. Global Neurosurgery sales rose 1.9%, led by Certas Plus, CUSA and Bactiseal, as better supply reliability helped Integra meet customer demand more consistently.
Instruments grew 3.2% organically, and management continues to expect full-year growth. Capital equipment declined about 1% as double-digit CUSA growth was offset by smaller-ticket systems, but management maintained a positive full-year capital outlook and described the hospital capital environment as healthy. Management continues to view ENT as an emerging opportunity, with innovation focused on navigation and eustachian tube technologies.
Image Source: Zacks Investment Research
Operational Execution and Braintree Capacity Ramp-Up: Integra’s transformation program is beginning to reduce operating friction, while Braintree adds a path to restore key products. In the second quarter of 2026, adjusted EPS increased 24.4% year over year and exceeded management’s guidance range. Adjusted gross margin improved 60 basis points (bps) to 61.3%, while adjusted EBITDA margin expanded 160 bps to 18.7%. Management kept its full-year 2026 adjusted EPS guidance unchanged at $2.40-$2.50.
The company still expects $25-$30 million of savings in 2026, with another $10-$15 million of annualized savings in 2027 as remediation and transformation costs decline. Braintree began production in June 2026 and is building inventory for a phased SurgiMend relaunch later in the year. Management does not expect SurgiMend to contribute meaningfully to 2026 revenues but expects sales to recover gradually over several quarters following the relaunch. SurgiMend premarket approval (PMA) is expected earlier in 2027, with DuraSorb later that year, subject to FDA inspection and approval.
Tissue Reconstruction Recovery and Portfolio Returns: Tissue Reconstruction is supported by product breadth across biologic and synthetic wound solutions, although performance across the business remains mixed. In the second quarter of 2026, revenues were $109.5 million, down 2% organically, as DuraSorb growth and PriMatrix gains were offset by lower Integra Skin and MicroMatrix sales. Integra Skin increased sequentially from the first quarter, with management expecting that progression to continue through 2026.
Roughly nine months after its relaunch, PriMatrix had recovered slightly more than half of pre-recall revenues and continued to rise sequentially. Wound reconstruction was about flat for the first half of 2026, consistent with full-year expectations. The hospital-heavy mix also limits exposure to outpatient skin-substitute reimbursement changes. MediHoney is expected to return to the market in 2027. Continued customer interest in the product could support further recovery in the Tissue Reconstruction portfolio.
What Concerns Integra?
Elevated Leverage: Integra ended the second quarter of 2026 with total liquidity of about $496 million, including $274 million of cash and short-term investments. Net debt remained high at $1.60 billion. Total leverage improved to 4.1X from 4.5X at year-end 2025 but remained above management’s 2.5X-3.5X target range. Interest expense increased to $23.0 million from $21.0 million a year earlier. Management also expects higher interest expense in the second half of 2026 as it evaluates refinancing options, which could constrain financial flexibility.
Foreign Exchange Volatility Persists: Integra’s international exposure leaves reported revenues sensitive to currency movements. In the second quarter of 2026, management lowered full-year reported revenue guidance to $1.654-$1.695 billion from $1.662-$1.702 billion solely because of a stronger U.S. dollar.
IART Stock Estimate Trend
The Zacks Consensus Estimate for the company’s 2026 earnings per share (EPS) has remained constant at $2.46 in the past 60 days.
The consensus estimate for the 2026 revenues is pegged at $1.68 billion. This suggests a 2.5% rise from the year-ago reported number.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Veracyte (VCYT - Free Report) , Phibro Animal Health (PAHC - Free Report) and Globus Medical (GMED - Free Report) .
Veracyte has an earnings yield of 4.7% against the industry’s negative 1.4% yield. Shares of the company have risen 34.3% compared with the industry’s 11.1% growth. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
VCYT sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Phibro Animal Health, sporting a Zacks Rank #1, has an earnings yield of 10.2% compared with the industry’s 2.5% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 18.4%. PAHC shares have fallen 12.2% against the industry’s 27.3% decline over the past year.
Globus Medical, sporting a Zacks Rank #1, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 32.2% compared with the industry’s 11.1% growth over the past year.